<DOC>
	<DOCNO>NCT02331940</DOCNO>
	<brief_summary>The aim study compare tiotropium Respimat Soft Mist Inhaler HandiHaler term effect sleep oxygen saturation ( SaO2 ) sleep quality patient COPD .</brief_summary>
	<brief_title>Tiotropium Respimat Versus HandiHaler SaO2 Sleep COPD Patients</brief_title>
	<detailed_description>Patients chronic obstructive pulmonary disease ( COPD ) poor sleep quality result various alteration oxygenation parameter sleep macro- micro-architecture . We aim compare tiotropium Respimat Soft Mist Inhaler HandiHaler term effect sleep oxygen saturation ( SaO2 ) sleep quality patient COPD . In randomized , parallel-group trial involve 200 patient mild moderate COPD ( rest arterial oxygen tension &gt; 60 mmHg awake ) , compare effect 6 month ' treatment two device sleep SaO2 sleep quality .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male female patient age &gt; =40 year old current exsmokers smoke history least 10 packyears mild moderate stable COPD ( Global Initiative Chronic Obstructive Lung Disease [ GOLD ] Stage I II accord 2010 GOLD guideline ( postbronchodilator force expiratory volume first second ( FEV1 ) ≥80 % predicted stage I 50 % ≤ FEV1 &lt; 80 % predict stage II , postbronchodilator FEV1/forced vital capacity ( FVC ) ratio &lt; 0.70 screen ) wake arterial oxygen tension ( PaO2 ) ≥60 mmHg refusal participate respiratory tract infection within 4 week prior screen COPD exacerbation require treatment antibiotic and/or oral corticosteroid and/or hospitalization within 6 week prior screen concomitant pulmonary disease COPD asthma evidence sleep apnea baseline sleep study obesity hypoventilation syndrome respiratory failure congestive heart failure history lifethreatening arrhythmias cardiomyopathy longQT syndrome QTc &gt; 450 m screen diabetes longterm oxygen therapy symptomatic prostatic hyperplasia bladderneck obstruction moderate/severe renal impairment urinary retention narrowangle glaucoma family personal history mental illness drug alcohol abuse severe cognitive impairment concurrent oncological disease history narcolepsy restless legs syndrome know history alpha1 antitrypsin deficiency participation active phase supervise pulmonary rehabilitation program hypersensitivity test ingredient history adverse reaction inhale anticholinergic .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>sleep oxygen saturation</keyword>
	<keyword>sleep quality</keyword>
</DOC>